- New 58,000-square-foot facility will simplify and accelerate the production of downstream processing equipment, including chromatography technologies and time- and cost-saving tangential flow filtration
- Dedicated space for demonstration and factory acceptance testing of instruments and systems
HAVANT, UK, April 16, 2021 / B3C newswire / -- Sartorius, a leading international partner of life science research and the biopharmaceutical industry, will open a new state-of-the-art manufacturing facility in Havant, Hampshire, UK. The opening marks the official relocation of more than 90 employees to the new facility, located just a few miles away from the former site in Portsmouth.
“The new facility in Havant will be an important part of our global operations network as it will enable our business to grow to meet the requirements of the expanding industry,” said Dr. Thorsten Peuker, Head of Operations, BPS Systems at Sartorius.
The 58,000-square-foot site is in close proximity to Portsmouth’s substantial talent pool, enabling the company to bring together skilled engineers with biochemical, electrical, and mechanical backgrounds who will design and manufacture a range of systems for the biopharmaceutical market, including chromatography columns and time- and cost-saving filtration systems. These systems are crucial for manufacturing injectable drugs used to treat cancer and diabetes and for producing vaccines to prevent the spread of viruses.
In addition to a 28,000-square-foot production area, the center accommodates a 4,000-square-foot customer test lab to demonstrate the functionality of Sartorius equipment. “The new facility increases Sartorius’ capacity to deliver support in all areas of our business and provide the highest quality equipment and services to our customers,” said Peuker.
In 2021, Sartorius will invest more than 400 million euros in the expansion of manufacturing capacities around the world to meet the high demand from the growing biopharmaceuticals market. In line with these investment, Sartorius aims to expand its Havant site, and the company is now offering positions for process engineers, project managers, and design engineers, as well as for several support functions, among other job vacancies. With its new facility in Havant, Sartorius now has five locations in the UK, employing over 900 staff members. Background: In April 2020, Sartorius acquired selected life science businesses from Danaher Corporation, including a production facility for downstream processing equipment in Portsmouth, UK. Sartorius decided to relocate the team to an advanced facility that provides higher capacity and is located just a few miles away from the former site.
About Sartorius
The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions complementary technologies. In fiscal 2020, the company earned sales revenue of some 2.34 billion euros. At the end of 2020, nearly 11,000 people were employed at the Group’s approximately 60 manufacturing and sales sites, serving customers around the globe.
Contact
Timo Lindemann
Corporate Communications
+49 (0)551.308.4724
This email address is being protected from spambots. You need JavaScript enabled to view it.
sartorius.com
Follow Sartorius on Twitter @Sartorius_Group and on LinkedIn.
Keywords: Industry; Life Science; Biological Products; Bioreactors; Pharmaceutical Production; Manufacturing; Chromatography; Filtration; Commerce; Manufacturing and Industrial Facilities; Biotechnology; United Kingdom
Published by B3C newswire